Navigation Links
Adult cancer drugs show promise against an aggressive childhood brain tumor
Date:3/27/2014

nical trial."

Based on results from this and previous studies, pemetrexed and gemcitabine were included in a St. Jude-led multicenter clinical trial of children and adolescents newly diagnosed with medulloblastoma. The drugs are already approved for treatment of patients with advanced breast cancer as well as ovarian, pancreatic and certain lung cancers. No safety concerns were identified in previous studies of pemetrexed and gemcitabine for treatment in children with other cancers.

Most group 3 medulloblastoma tumors feature excessive levels of the c-MYC protein, which helps to regulate cell growth. The protein is overexpressed in many cancers and is associated with a poor outcome. About 40 percent of patients with c-MYC overexpression and other characteristics of group 3 medulloblastoma become long-term survivors, compared to 80 percent of other medulloblastoma patients.

"The drugs identified in this study will hopefully close that survival gap and improve cure rates for children with group 3 medulloblastoma," said co-author Amar Gajjar, M.D., St. Jude Department of Oncology co-chair.

For this study, researchers relied on mice with group 3 medulloblastoma grown from patient tumors. The mice were developed in Roussel's laboratory and are a powerful tool for testing the effectiveness of drugs against human tumors. Researchers used the mice to show that pemetrexed and gemcitabine worked against human group 3 tumors and that the drugs could be used in combination with existing chemotherapy agents to boost treatment effectiveness without undue risk. Cisplatin and cyclophosphamide were the other drugs used in this study.

"The finding provides a strong rationale for combination therapy with pemetrexed and gemcitabine for treatment of group 3 medulloblastoma," Roussel said. Researchers found no evidence that mouse tumor cells develop resistance to the drugs.

Pemetrexed works by disrupting the ability of cancer cells t
'/>"/>

Contact: Carrie Strehlau
carrie.strehlau@stjude.org
901-595-2295
St. Jude Children's Research Hospital
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Infection Might Raise Blood Clot Risk for Older Adults: Study
2. EKG Heart Test May Predict Risk in Older Adults
3. Unique approach needed to accurately assess health of young adult cancer survivors
4. Out-of-hand tree nut consumption associated with better diet quality in children and adults
5. Symptomatic behaviour in childhood strongly predicts psychiatric treatment as a young adult
6. Gay Adults Rejected by Parents Have Worse Health, Study Finds
7. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
8. Callahan honored for improving older adults health in their doctors offices
9. Anti-tobacco TV ads help adults stop smoking, study finds
10. Childhood Obesity May Raise Odds of Adult Liver Cancer
11. Better health in adulthood starts with early prevention in childhood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... (PRWEB) May 06, 2015 Wolters ... healthcare professionals and students, announced today that in a ... confirmed that use of the clinical decision support resource ... the end of 2014, UpToDate users in more than ... topics per month, on average. In Germany alone, 95% ...
(Date:5/6/2015)... TX (PRWEB) May 06, 2015 ... 1,000 user mark after launching in mid-February. The company ... candidates who have previous experience in the industry. Likewise, ... profession. , According to Kyle Johnson, CTO, unique traffic ... to the first month: "Each new job posting brings ...
(Date:5/6/2015)... 06, 2015 Locally owned, Greek olive oil ... this past week as having one the best Extra Virgin ... from the Peloponnese region of Greece and known as ... the category of Medium Olive Oil, which is defined by ... With over 700 producer applicants from 25 different countries ...
(Date:5/6/2015)... Dr. Vito C. Quatela, one of upstate New York’s ... medical mission trip to Hanoi, Vietnam with the HUGS Foundation ... and other deformities of the face. , During the 10-day ... 26, Dr. Quatela and his team performed microtia surgeries on ... the outside of the ear is underdeveloped. This condition is ...
(Date:5/6/2015)... Los Angeles, California (PRWEB) May 06, 2015 ... has secured its first round of VC funding and ... , The enterprise class embeddable software enables applications ... transform data as it moves between systems and locations. ... the HyperTransfer technology moves files at line speed, independent ...
Breaking Medicine News(10 mins):Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Job Seekers Turn to JobMedic to Find Healthcare Positions - JobMedic.com Reaches 1,000 User Milestone 2Health News:Greek Extra Virgin Olive Oil, Laconiko Wins Gold at the NYIOOC and Is Featured in Olive Oil Times as One of Greece's Best EVOO's for 2015 2Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 2Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 3Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 2Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 3Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 4
... completely implantable artificial heart was approved by the U.S. ... heart has been approved for patients with severe heart ... ,Under the FDA's Humanitarian Use Device provisions, ... However, it restricts the use of more than 4,000 ...
... 300 million poultry next month against bird flu.// ... large-scale criticism over the country's efforts to stamp out ... mass vaccination today. Indonesia has the world's highest human ... in the world and scientists and the World Bank ...
... An engineer has developed a new system that could help ... ,An engineer Fernando Silvio Nu?o Almirantearena has developed a ... heart attack, brain stroke or high blood pressure, by determining ... techniques. Fernando has outlined in his thesis for PhD the ...
... in the Journal of Clinical Investigation and the September issue ... that a new drug helps in reducing the risk of ... flow in diseased arteries. The new drug developed by ... by free radicals, which helps in dilatation of the arteries. ...
... worked at Ground Zero after 9/11 are struggling with serious ... advocates.// "When we were needed on 9/11, no one asked ... said Lucelly Gil, who was present in the disaster zone. ... illegal immigrants to work in danger zone without providing the ...
... asked EU health authorities to re-examine data related to ... Committee for Medicinal Products for Human Use (CHMP) had ... cancer need new treatment options like Tarceva, which has ... and has already been approved for this indication in ...
Cached Medicine News:Health News:First Implantable artificial heart gets FDA’s approva 2Health News:Indonesia To Conduct Mass Vaccination Of Poultry 2Health News:A New System Developed For Studying The Condition Of The Human Arterial System 2Health News:A New Drug That Could Revolutionize Management Of Heart Disease 2
(Date:5/6/2015)... , May 06, 2015 Research and Markets ... addition of the "Asia-Pacific Internal Trauma Fixation ... Analysis and Forecast To 2019" report to ... Fixation Devices market is estimated to grow at ... Factors, such as technological advancement, rising incidences of ...
(Date:5/6/2015)... DIEGO , May 6, 2015  MEI Pharma, Inc. ... clinical development of novel therapies for cancer, announced today that ... Officer, will present at the Bank of America Merrill Lynch ... 8:00 a.m. Pacific time from the Encore at the Wynn ... of the presentation can be accessed at www.meipharma.com . ...
(Date:5/6/2015)... 6, 2015 Adaptive Biotechnologies, a leader ... T-cell and B-cell receptors in the immune system, ... financing round with a $195 million investment to ... led by Matrix Capital Management and included other ... Springs Capital and an additional large healthcare investor, ...
Breaking Medicine Technology:Asia-Pacific Internal Trauma Fixation Devices (Internal Trauma Fixation Plates, Screws, Rod Wires & Pins, Fusion Nails) Market 2015 2MEI Pharma to Present at Bank of America Merrill Lynch Health Care Conference 2Adaptive Biotechnologies Enhances Leading Position in Growing Immunosequencing Market with Completion of $195 Million Investment 2
... MYL ) today announced its financial results for the ... , Adjusted diluted EPS of $0.52 for the three ... prior year period, an increase of 18%; , Adjusted ... 31, 2012 compared to $1.45 billion for the same prior year ...
...  Galenea Corp., a leader in the rapidly emerging ... Stanley Medical Research Institute (SMRI) will provide $6 ... development of Galenea,s innovative pro-cognitive discovery program and ... treatment of schizophrenia and other psychiatric disorders.  The ...
Cached Medicine Technology:Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 2Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 3Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 4Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 5Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 6Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 7Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 8Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 9Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 10Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 11Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 12Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 13Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program 2Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: